肝细胞癌患者血清癌基因和抑癌基因蛋白水平变化

目的 探讨肝细胞癌(HCC)患者血清常见的癌基因和抑癌基因水平变化.方法 2017年7月～2020年7月我院收治的慢性乙型肝炎患者40例,代偿期乙型肝炎肝硬化患者25例,失代偿期乙型肝炎肝硬化患者31例,HCC患者50例和同期体检的健康人40例,采用ELISA法检测血清癌基因转化基因(N-ras)、增殖相关基因(C-m...

Serum oncogene and tumor suppressor gene levels in patients with hepatocellular carcinoma

Objective The aim of this study was to investigate serum oncogene and tumor suppressor gene level changes in patients with hepatocellular carcinoma(HCC).Methods 40 patients with chronic hepatitis B(CHB),25 patients with compensated hepatitis B liver cirrhosis(LC),31 patients with decompensated hepatitis B LC,50 patients with HCC and 40 healthy persons were enrolled in our hospital between July 2017 and July 2020,and serum oncogene transformation of participants(Nras),proliferation related genes(C-myc),fibroblast growth factor(FGF)2,silk/threonine kinase(PLK)1 as well as tumorsuppressor genes iron element(hepcidin),scavenger receptors(SCAR)A5,and cell cycle dependent protein kinase inhibitor(P16)protein were detected by ELISA.Results Serum N-ras,C-myc,FGF2 and PLK1 levels in patients with HCC were(17.9±2.4)pg/mL,(16.2±2.0)pg/mL,(19.0±3.2)pg/mL and(15.4±1.9)pg/mL,all significantly higher than【(10.3±1.4)pg/mL,(10.0±1.2)pg/mL,(10.2±1.4)pg/mL and(9.0±1.1)pg/mL,respectively,P<0.05】in patients with decompensated LC or【(9.9±1.2)pg/mL,(9.9±1.1)pg/mL,(10.0±1.3)pg/mL and(9.1±1.0)pg/mL,respectively,P<0.05】in patients with compensated LC or【(9.8±1.1)pg/mL,(9.7±1.1)pg/mL,(9.9±1.2)pg/mL and(9.0±1.0)pg/mL,respectively,P<0.05】in patients with CHB or【(1.2±0.2)pg/mL,(1.1±0.1)pg/mL,(1.1±0.2)pg/mL and(0.9±0.1)pg/mL,respectively,P<0.05】in healthy persons;serum hepcidin,SCARA5 and P16 levels in patients with HCC were(1.1±0.3)pg/mL,(1.3±0.3)pg/mL and(1.7±0.4)pg/mL,all significantly lower than【(5.3±0.7)pg/mL,(7.2±1.1)pg/mL and(6.4±0.8)pg/mL,respectively,P<0.05】in patients with decompensated LC or【(5.6±0.8)pg/mL,(7.3±1.1)pg/mL and(6.3±0.8)pg/mL,respectively,P<0.05】in patients with compensated LC or【(5.4±0.7)pg/mL,(7.9±1.1)pg/mL and(6.5±1.0)pg/mL,respectively,P<0.05】in patients with CHB or【(12.9±1.2)pg/mL,(14.4±1.3)pg/mL and(11.6±0.9)pg/mL,respectively,P<0.05】in healthy individuals.Conclusion The up-regulation of N-ras,c-myc,FGF2 and PLK1 and down-regulation of hepcidin,scara5 and p16 occur in patients with HCC,which might be involved in the hepatocarcinogenesis.